Authors: SCHER H BAHNSON R COHEN S EISENBERGER M HERR H KOZLOWSKI J LANGE P MONTIE J POLLACK A RAGHAVEN D RICHIE J SHIPLEY W

Citation: H. Scher et al., NCCN UROTHELIAL CANCER PRACTICE GUIDELINES, Oncology, 12(7A), 1998, pp. 225-271

Authors: BAHNSON R BROSMAN S GREENBERG R BROWN BT DALKIN B MIDDLETON R SOLOWAY M STEINBERG G WAJSMAN Z

Citation: R. Bahnson et al., MULTICENTER EFFICACY AND SAFETY STUDY OF INTRAVESICAL AD-32 (VALRUBICIN) IN THE TREATMENT OF PATIENTS WITH REFRACTORY BLADDER-CARCINOMA IN-SITU, The Journal of urology, 159(5), 1998, pp. 551-551

Authors: SODEE DB CONANT R CHALFANT M MIRON S KLEIN E BAHNSON R SPIRNAK P CARLIN B BELLON EM ROGERS B

Citation: Db. Sodee et al., PRELIMINARY IMAGING RESULTS USING IN-111 LABELED CYT-356 (PROSTASCINT(TM)) IN THE DETECTION OF RECURRENT PROSTATE-CANCER, Clinical nuclear medicine, 21(10), 1996, pp. 759-767

Authors: BERGER BM NAADIMUTKU A BODDY A FISHER HA MCCONNELL JD MILAM D MOBLEY D RAJFER J ADAMS G AIGEN AB BOYD S NARAYAN P ANDRIOLE G BAHNSON R BELVILLE W TOPLEY HM BLOCK N EPSTEIN HB LAZAN DW BAKULE PT BOYLE ET FERRIGNI R BRANNAN W BRAWER MK FOSS F COX CE SMITH J ELHILALI M GOLDENBERG L SULLIVAN L NORMAN R LAWEN JG TRACHTENBERG J LEPOR H KANDZARI S LABASKY R KALISH M PICKETT SH

Citation: Bm. Berger et al., THE EFFECT OF ZANOTERONE, A STEROIDAL ANDROGEN RECEPTOR ANTAGONIST, IN MEN WITH BENIGN PROSTATIC HYPERPLASIA, The Journal of urology, 154(3), 1995, pp. 1060-1064

Authors: LOGAN TF SHANNON W BRYANT J KANE P WOLMARK N POSNER M KIRKWOOD JM ERNSTOFF MS FUTRELL JW STRAW LD IWATUSKI S BAHNSON R

Citation: Tf. Logan et al., PREPARATION OF VIABLE TUMOR-CELL VACCINE FROM HUMAN SOLID TUMORS - RELATIONSHIP BETWEEN TUMOR MASS AND CELL YIELD, Melanoma research, 3(6), 1993, pp. 451-455